Lv41
650 积分 2023-09-12 加入
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
2个月前
已完结
Orally Active Peptides: Is There a Magic Bullet?
1年前
已完结
Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability
1年前
已完结
Encouraging results for first oral IL-23 receptor antagonist in plaque psoriasis
1年前
已关闭
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
1年前
已完结
First-in-Human Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAR443820, a Central Nervous System Penetrant RIPK1 Inhibitor in Healthy Participants (S46.005)
1年前
已关闭
Progress and limitations of oral peptide delivery as a potentially transformative therapy
1年前
已完结
Oral Administration of Peptide-Based Drugs: Beyond Lipinski's Rule
1年前
已完结
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers
1年前
已完结
Strategies to improve the physicochemical properties of peptide-based drugs
1年前
已完结
皖公网安备34019202002308
